Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review. by Ali, I et al.
1Ali I, et al. BMJ Paediatrics Open 2019;3:e000572. doi:10.1136/bmjpo-2019-000572
Open access 
Healthcare utilisation in children with 
SMA type 1 treated with nusinersen: a 
single centre retrospective review
Imran Ali  ,1 Francis J Gilchrist  ,1,2 William D Carroll,1,2 John Alexander,1 
Sadie Clayton,1 Richa Kulshrestha,3 Tracey Willis,3 Martin Samuels  1 
To cite: Ali I, Gilchrist FJ, 
Carroll WD, et al. Healthcare 
utilisation in children with SMA 
type 1 treated with nusinersen: 
a single centre retrospective 
review. BMJ Paediatrics Open 
2019;3:e000572. doi:10.1136/
bmjpo-2019-000572
Received 23 August 2019
Revised 30 October 2019
Accepted 2 November 2019
1Paediatric Respiratory Service, 
University Hospital of North 
Midlands NHS Trust, Stoke- on- 
Trent, UK
2Institute of Applied Clinical 
Science, Keele University, Keele, 
UK
3Muscle Team, Robert Jones 
and Agnes Hunt Orthopaedic 
and District Hospital NHS Trust, 
Oswestry, UK
Correspondence to
Dr Martin Samuels;  martin. 
samuels@ uhnm. nhs. uk
Original research
© Author(s) (or their 
employer(s)) 2019. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
What is already known on this topic?
 ► Nusinersen improves prognosis and life expectan-
cy in children with spinal muscular atrophy type 1 
(SMA1).
 ► Infants are now surviving with considerable depen-
dency on healthcare services.
 ► The UK’s National Institute for Health and Care 
Excellence agreed to fund this new treatment in May 
2019.
What this study adds?
 ► Children with SMA1 who receive nusinersen have 
significant ongoing medical costs in addition to the 
cost of the drugs received.
 ► On average this currently is more than £100 000 per 
patient per year in the first two years of follow- up.
 ► Associated healthcare costs reduce as time pro-
gresses and are less in the second year of life.
AbstrACt
background Nusinersen has been used to treat spinal 
muscular atrophy type 1 (SMA1) in the UK since 2017. 
While initial trials showed neuromuscular benefit from 
treating SMA1, there is little information on the respiratory 
effects of nusinersen. We aimed to look at the respiratory 
care, hospital utilisation and associated costs in newly 
treated SMA1.
Methods We reviewed the medical records of all 
children within the West Midlands with SMA1 treated with 
nusinersen at Royal Stoke University Hospital. Baseline 
demographics and hospital admission data were collected 
including: the reason for admission, total hospital days, 
days of critical care, days intubated, discharge diagnosis, 
doses of nusinersen and treatment complications.
results 11 children (six girls) received nusinersen 
between May 2017 and April 2019. Their median (range) 
age was 29 (7–97) months. The median (range) number of 
nusinersen doses per child was 6 (4–8). All children were 
receiving long- term ventilatory support; this was mask 
ventilation in nine and tracheostomy ventilation in two. 
The total number of hospital days since diagnosis was 
1101 with a median (range) of 118 (7–235) days per child. 
This included general paediatric ward days 0 (0–63), High 
Dependency Unit 79 (7–173) days and Paediatric Intensive 
Care Unit 13 (0–109) days per child. This equated to a 
median (range) of 20 (2–72) % of their life in hospital. The 
estimated cost of this care was £2.2M.
Conclusion Patients with SMA1 treated with nusinersen 
initially spend a considerable proportion of their early life 
in hospital. Parents should be counselled accordingly. 
These data suggest that for every 10 children started 
on nusinersen an extra HDU bed is required. This has a 
significant cost implication.
bACkground
Spinal muscular atrophy (SMA) is an auto-
somal recessive neuromuscular disorder char-
acterised by progressive muscular atrophy 
and weakness.1 It has an incidence of one 
in 11 000 live births.2 There are various 
subgroups of SMA classified clinically, with 
SMA type 1 (SMA1) accounting for approx-
imately 60% of cases, and carrying the worst 
prognosis.3 Until recently, SMA1 was the most 
common genetic disease resulting in death 
in infancy.4 Affected children usually present 
with symptoms before 6 months of age and 
historically died from respiratory failure by 
the age of 2 years.5
SMA1 is caused by the homozygous deletion 
or mutation of the survival motor neuron 1 
(SMN1) gene. This results in reduced expres-
sion of the SMN protein, which is essential for 
the survival of motor neurones in the spinal 
cord and brain stem.6 Inadequate expres-
sion of SMN protein causes degeneration of 
the motor neuron which in turn causes the 
associated muscles to atrophy. Humans have 
a variable number of copies of a second gene, 
SMN2 which also encodes for SMN protein.6 
However, SMN2 transcription in 80%–90% of 
instances leads to production of a truncated, 
unstable form of the protein which is non- 
functional. Approximately 80% of infants 
with SMA1 have only one or two copies of 
SMN2 and are therefore unable to produce 
enough functional SMN protein to support 
normal muscle development.
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Table 1 Characteristics of cohort
Median Range
Age at diagnosis (months) 6.5 3.5–21
Age of first dose nusinersen (months) 8.1 0–85.7
Age at initiation of Long Term Ventilation 
(months)
8.1 2.3–36.5
Age at initiation of advanced care 
pathway (n=4) (months)
21.3 7.1–70.8
Number of admissions per child* 11 1–25
Number of emergency admissions per 
child*
3 0–21
Number of elective admissions per 
child*
4 0–9
Hospital days per child* 84 7–235
General paediatric hospital days per 
child*
0 0–63
HDU days per child* 79 7–173
PICU days per child* 13 0–109
*Over 24 months.
Nusinersen is an antisense oligonucleotide which works 
by binding to the SMN2 mRNA and in order to be effec-
tive it must be delivered into the cerebrospinal fluid. This 
binding modifies splicing of the SMN2 gene to promote 
increased production of functional SMN protein.7 Treat-
ment with nusinersen has the potential to transform 
prognosis for these children offering hope of treatment 
for the first time. The drug has been used in the UK since 
early 2017. The drug costs £450 000 in the first year and 
£225 000 per annum subsequently. For patients beginning 
this before November 2018, the manufacturer provided 
it free through an Expanded Access Programme.8 The 
National Health Service in England (NHSE) commis-
sions an administration cost, but not the other aspects 
of care for these patients. While randomised controlled 
trials showed nusinersen improved motor function and 
development,7 it is unclear whether the respiratory conse-
quences produce similar benefits and thus the demands 
of treatment for families and health economies is yet to 
be established.
Royal Stoke University Hospital (RSUH) is the 
regional centre for nusinersen administration in the 
West Midlands which has a population of approximately 
6 million. In March 2019 RSUH had the second largest 
cohort of SMA1 patients in the UK. Before agreeing to act 
as a regional centre for nusinersen delivery, we carefully 
considered the potential effects on children, their fami-
lies and other healthcare services. However, data were 
lacking making counselling of families and planning of 
service provision difficult. We have carefully monitored 
healthcare utilisation of SMA1 children treated with 
nusinersen. The aim of this article is to report the data 
on service utilisation for these children to assist families 
and healthcare professionals.
Methods
Patients treated with intrathecal nusinersen at RSUH were 
identified from a local database. The paper notes and 
electronic clinical records were reviewed to collect rele-
vant data from RSUH and the child’s referring hospital. 
This included baseline demographics, age at diagnosis, 
details of ventilatory support, feeding support, number 
of nusinersen doses, complications following adminis-
tration and details of all hospital admissions. Hospital 
admission data included: duration of admission, number 
of High Dependency Unit (HDU) days, Paediatric Inten-
sive Care Unit (PICU) days and intubated days. Nusin-
ersen usually necessitated admission for one night for 
the first dose only. All children received care in accord-
ance with the published international guidelines for the 
care of children with SMA.9 10 Intrathecal nusinersen was 
administered by appropriately trained paediatricians in 
the PICU treatment room. In babies this was performed 
using local anaesthetic and in toddlers using low dose 
opiate analgesia and/or sedation. No child has required 
a general anaesthetic or interventional radiology.
results
We identified eleven children (six girls) who received 
nusinersen through the Expanded Access Program at 
RSUH between May 2017 and April 2019. Parents of a 
twelfth child declined nusinersen and the child died at 
3 months of age. The median (range) number of nusin-
ersen doses was 6.4–8 Nine children received mask venti-
lation and two children were ventilated via tracheostomy 
(TIV). Six children had been commenced on ventila-
tion prior to their first dose of nusinersen. Both patients 
receiving TIV had the tracheostomy inserted before 
nusinersen was commenced. Two patients (including 
one on tracheostomy ventilation) have died suddenly at 
home from presumed mucous plugs at 12 and 16 months 
of age, while one other patient had a cardiorespiratory 
arrest and has suffered hypoxic brain injury.
duration and location of admissions
In 24 months, the 11 children had spent a total of 
1101 days in hospital. Details of the hospitalisation are 
summarised in table 1. Three children were responsible 
for all admissions to the general paediatric ward which 
occurred at their local hospital. During these admissions, 
the respiratory team at RSUH liaised closely with local 
providers to guide acute management and arranged 
transfer when necessary. Three children had not been 
admitted to PICU. Of the eight children that had, six had 
been intubated for a total of 38 days. The median (range) 
proportion of life spent in hospital was 20% (2%–72%). 
This was variable with four children spending ≤10%, four 
10%–35% and three >35%.
reason for admission
The median age (range) for initiation of nusinersen 
was 8.1 (0 - 85.7) months. Since initiation of nusinersen 
the 11 children had a total of 107 hospital admissions 
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Table 2 Physiotherapy adjuncts that SMA1 children 
required
Physiotherapy adjunct
Number (percentage) of 
children requiring adjunct
Saline nebulisers 8 (72%)
Suction 11 (100%)
Percussion 9 (82%)
Cough assist machine 5 (45%)
High frequency chest wall 
oscillation vest
1 (9%)
SMA1, spinal muscular atrophy type 1.
Figure 1 Total hospital days per month spent by children 
following commencement on nusinersen.
Figure 2 Median length of hospital stay per admission for 
all children.
with a median (range) per child of 11 (1–25). The most 
common reason for admission was lower respiratory tract 
infection (n=42), followed by elective administration of 
intrathecal nusinersen (n=38). There were seven admis-
sions for gastrointestinal issues, six for an elective sleep 
study, five for aspiration pneumonia, four for increased 
secretions or airway issues and three for optimisation of 
ventilatory support. At each admission for nusinersen the 
patient and family were reviewed by the paediatric palli-
ative care team who administered intrathecal treatment 
and assessed palliative needs. Children also received phys-
iotherapy while inpatients. The physiotherapy adjuncts 
used by patients are listed in table 2. Four children 
had advanced care pathways in place. Between hospital 
admissions all the children were reviewed regularly in 
the outpatient clinic by the multi- disciplinary members 
of the Paediatric Respiratory Service.
trends in admissions
Children in our cohort had the greatest requirement 
for hospital admission in the first 6 months following 
nusinersen initiation (see figure 1). Much of this effect 
is driven by a tendency for children to have a long first 
admission (see figure 2). Subsequent admissions tend to 
be shorter. The total number of hospital days for the chil-
dren’s first admission was 426 days with a median (range) 
of 20 (1–235) days per child.
Cost implications and impact on local services
A total of 762 HDU days and 248 PICU days were 
required by the 11 children in our cohort over 2 years. 
This equates to 2.8 days in HDU and 0.93 days in PICU 
per child each month. RSUH has six HDU (four acute 
HDU beds and two long term ventilation) and eight 
PICU beds. The children therefore occupied 17% of the 
total HDU capacity and 4.2% of the PICU capacity over 
the study period. Based on current estimates of £1626 per 
day for an HDU bed and £1785 to £3784 for a PICU bed 
(depending on the level of care), the additional cost of 
these HDU/PICU days is £2.2M.11 This is separate to the 
cost of the nusinersen and its administration.
In addition to the costs associated with inpatient care, 
these children frequently require care packages which 
incur additional community costs. These costs are likely to 
continue throughout the child’s life. In this small cohort, 
we found families highly motivated to provide care for 
their children and no child experienced a prolonged 
hospital admission as a result of awaiting funding for the 
provision of a care package. Four children had care pack-
ages implemented: one child had 16 hours of care a week 
and three of the children had over 85 hours care per 
week. These three children received care seven nights a 
week between 9–10 hours and 3 days a week between 5 
and 8 hours. One with a large care package had tracheos-
tomy ventilation, but the parents of the other child with 
tracheostomy declined a care package.
disCussion
This is the first study which reports the inpatient health-
care utilisation of a cohort of children treated with 
nusinersen. This information is vital for those planning 
hospital healthcare services. In the first 2 years after 
diagnosis, these children spend, on average, one fifth 
of their early life in hospital although there is consider-
able inter- individual variation. This places a significant 
burden on parents and families and they should be coun-
selled accordingly. There is a considerable impact on 
hospital services, particularly on high dependency and 
PICU. However, not all children required PICU admis-
sion and not all children admitted to PICU required 
endotracheal intubation. This involves a substantial extra 
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resource, in addition to the direct cost of the nusinersen. 
Reassuringly, the number of hospital days has reduced 
as the child grows older. In our cohort, the 11 children 
required 762 HDU days over 24 months. This equates to 
the need for an additional HDU bed for every 10 chil-
dren commenced on nusinersen.
NHSE has decided to fund nusinersen for the next 
5 years so the numbers of SMA1 patients surviving 
and treated with nusinersen will increase, along with 
the demand on critical care and community services. 
Currently there is no ring- fenced funding for the health 
needs of SMA1 patients receiving nusinersen and this is 
something that must be explored to provide optimal care 
for these patients without affecting that of other children 
requiring critical care or general paediatric services. Only 
a small proportion of admissions was managed wholly at 
the children’s local hospital where expertise in NIV is 
being slowly developed.
We acknowledge the limitations of this study. It includes 
only eleven patients treated at one centre, although this 
is the second largest in the UK. The retrospective nature 
of the study may have introduced bias and we did not 
adjust for potential confounding factors such as socioeco-
nomic status and comorbidities. Given the small numbers 
of children in this cohort we have elected not to report 
a detailed phenotype and correlation to healthcare utili-
sation as any observed correlations may be spurious and 
open to misinterpretation. Instead, we have chosen to 
consider the cohort as a group as this allows funders, 
clinicians and those planning healthcare services to 
make better informed decisions. Estimates of the finan-
cial burden have concentrated on inpatient rather than 
community costs and will therefore be an underestimate. 
We could not undertake an accurate review of health-
care costs in our region for children with SMA1 prior to 
the introduction of nusinersen as most children did not 
receive active treatment and died in their local hospital. 
A recent German study estimated the total direct cost of 
illness for children with SMA1 to be €99 664 per year.12
As the children grow older, there is a fall in the 
number of days spent in hospital. This is in part due to 
a prolonged first admission, during which the child was 
stabilised and the family were trained and counselled. 
It may also be explained by: (1) a true improvement in 
the respiratory muscle strength of these children over 
time, or (2) a gradual improvement in the medical care 
provided, or (3) an improved ability of these families 
to cope with their medical conditions at home and in 
their own community or (4) deaths within our cohort. 
While an important consideration, mortality alone seems 
unlikely to be the sole driver of this effect as only two chil-
dren within the cohort have died. It may be a function of 
all of these and we hope that the first three factors will 
continue to operate.
Conclusion
While the improved prognosis and life expectancy asso-
ciated with nusinersen treatment is exciting for children 
with SMA1 and their families, we remain unsure that 
the respiratory benefits are as great as that shown for 
the neurological improvement in the preliminary trials. 
This study has highlighted that such children will spend 
a significant amount of their life in hospital, particularly 
in the first months after diagnosis. This places a signif-
icant burden on families and on the National Health 
Service in general. The long- term outcome for these chil-
dren is still unknown but the trend for a reduction in 
hospital days as the child grows older may be reassuring. 
Further prospective studies with larger patient numbers 
are required to more accurately quantify the longer term 
healthcare utilisation by these children and the associ-
ated financial burden.
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